Go Pro
→ It’s not about Greenland (From Porter & Company) (Ad)tc pixel Free ONT Stock Alerts

Oxford Nanopore Technologies (ONT) Competitors

Oxford Nanopore Technologies logo
GBX 156.02 +3.32 (+2.18%)
As of 09/11/2026 12:44 PM Eastern
Compare

ONT vs. ABC, OXB, SLN, AVCT, and HZD

Should you buy Oxford Nanopore Technologies stock or one of its competitors? Oxford Nanopore Technologies's main competitors and comparable companies include Abcam (ABC), Oxford Biomedica (OXB), Silence Therapeutics (SLN), Avacta Group (AVCT), and Horizon Discovery Group plc (HZD.L) (HZD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Oxford Nanopore Technologies compare to Abcam?

Abcam (LON:ABC) and Oxford Nanopore Technologies (LON:ONT) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, analyst recommendations, earnings, valuation and profitability.

Abcam has a net margin of 0.00% compared to Oxford Nanopore Technologies' net margin of -54.66%. Abcam's return on equity of 0.00% beat Oxford Nanopore Technologies' return on equity.

Company Net Margins Return on Equity Return on Assets
AbcamN/A N/A N/A
Oxford Nanopore Technologies -54.66%-35.45%-14.42%

18.9% of Oxford Nanopore Technologies shares are held by institutional investors. 2.5% of Oxford Nanopore Technologies shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Oxford Nanopore Technologies had 1 more articles in the media than Abcam. MarketBeat recorded 1 mentions for Oxford Nanopore Technologies and 0 mentions for Abcam. Oxford Nanopore Technologies' average media sentiment score of 1.33 beat Abcam's score of 0.00 indicating that Oxford Nanopore Technologies is being referred to more favorably in the news media.

Company Overall Sentiment
Abcam Neutral
Oxford Nanopore Technologies Positive

Oxford Nanopore Technologies has a consensus target price of GBX 198.60, indicating a potential upside of 27.29%. Given Oxford Nanopore Technologies' stronger consensus rating and higher probable upside, analysts plainly believe Oxford Nanopore Technologies is more favorable than Abcam.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Abcam
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Oxford Nanopore Technologies
0 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.83

Abcam has higher revenue and earnings than Oxford Nanopore Technologies. Oxford Nanopore Technologies is trading at a lower price-to-earnings ratio than Abcam, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Abcam£350.40M0.00N/A£0.06N/A
Oxford Nanopore Technologies£235M6.49-£175.21M-£12.50N/A

Summary

Oxford Nanopore Technologies beats Abcam on 7 of the 13 factors compared between the two stocks.

How does Oxford Nanopore Technologies compare to Oxford Biomedica?

Oxford Biomedica (LON:OXB) and Oxford Nanopore Technologies (LON:ONT) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, dividends, risk, profitability, media sentiment and valuation.

Oxford Biomedica has a net margin of -17.85% compared to Oxford Nanopore Technologies' net margin of -54.66%. Oxford Nanopore Technologies' return on equity of -35.45% beat Oxford Biomedica's return on equity.

Company Net Margins Return on Equity Return on Assets
Oxford Biomedica-17.85% -48.56% -12.67%
Oxford Nanopore Technologies -54.66%-35.45%-14.42%

Oxford Biomedica currently has a consensus target price of GBX 580.85, indicating a potential upside of 30.82%. Oxford Nanopore Technologies has a consensus target price of GBX 198.60, indicating a potential upside of 27.29%. Given Oxford Biomedica's higher probable upside, analysts clearly believe Oxford Biomedica is more favorable than Oxford Nanopore Technologies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Oxford Biomedica
0 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.80
Oxford Nanopore Technologies
0 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.83

In the previous week, Oxford Biomedica and Oxford Biomedica both had 1 articles in the media. Oxford Nanopore Technologies' average media sentiment score of 1.33 beat Oxford Biomedica's score of 0.22 indicating that Oxford Nanopore Technologies is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Oxford Biomedica
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Oxford Nanopore Technologies
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Oxford Biomedica has a beta of 1.1, indicating that its share price is 10% more volatile than the broader market. Comparatively, Oxford Nanopore Technologies has a beta of 0.956, indicating that its share price is 4% less volatile than the broader market.

32.4% of Oxford Biomedica shares are owned by institutional investors. Comparatively, 18.9% of Oxford Nanopore Technologies shares are owned by institutional investors. 43.3% of Oxford Biomedica shares are owned by insiders. Comparatively, 2.5% of Oxford Nanopore Technologies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Oxford Biomedica has higher earnings, but lower revenue than Oxford Nanopore Technologies. Oxford Biomedica is trading at a lower price-to-earnings ratio than Oxford Nanopore Technologies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Oxford Biomedica£168.74M3.19-£143.51M-£26.92N/A
Oxford Nanopore Technologies£235M6.49-£175.21M-£12.50N/A

Summary

Oxford Nanopore Technologies beats Oxford Biomedica on 8 of the 15 factors compared between the two stocks.

How does Oxford Nanopore Technologies compare to Silence Therapeutics?

Oxford Nanopore Technologies (LON:ONT) and Silence Therapeutics (LON:SLN) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, dividends, profitability, media sentiment, risk and valuation.

In the previous week, Oxford Nanopore Technologies had 1 more articles in the media than Silence Therapeutics. MarketBeat recorded 1 mentions for Oxford Nanopore Technologies and 0 mentions for Silence Therapeutics. Oxford Nanopore Technologies' average media sentiment score of 1.33 beat Silence Therapeutics' score of 0.00 indicating that Oxford Nanopore Technologies is being referred to more favorably in the media.

Company Overall Sentiment
Oxford Nanopore Technologies Positive
Silence Therapeutics Neutral

18.9% of Oxford Nanopore Technologies shares are owned by institutional investors. 2.5% of Oxford Nanopore Technologies shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Silence Therapeutics has lower revenue, but higher earnings than Oxford Nanopore Technologies. Oxford Nanopore Technologies is trading at a lower price-to-earnings ratio than Silence Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Oxford Nanopore Technologies£235M6.49-£175.21M-£12.50N/A
Silence Therapeutics£11.35M0.00N/A-£48.60N/A

Silence Therapeutics has a net margin of 0.00% compared to Oxford Nanopore Technologies' net margin of -54.66%. Silence Therapeutics' return on equity of 0.00% beat Oxford Nanopore Technologies' return on equity.

Company Net Margins Return on Equity Return on Assets
Oxford Nanopore Technologies-54.66% -35.45% -14.42%
Silence Therapeutics N/A N/A N/A

Oxford Nanopore Technologies presently has a consensus price target of GBX 198.60, indicating a potential upside of 27.29%. Given Oxford Nanopore Technologies' stronger consensus rating and higher possible upside, analysts clearly believe Oxford Nanopore Technologies is more favorable than Silence Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Oxford Nanopore Technologies
0 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.83
Silence Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Summary

Oxford Nanopore Technologies beats Silence Therapeutics on 9 of the 13 factors compared between the two stocks.

How does Oxford Nanopore Technologies compare to Avacta Group?

Avacta Group (LON:AVCT) and Oxford Nanopore Technologies (LON:ONT) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, media sentiment, analyst recommendations, profitability, risk and dividends.

Oxford Nanopore Technologies has a net margin of -54.66% compared to Avacta Group's net margin of -33,961.06%. Oxford Nanopore Technologies' return on equity of -35.45% beat Avacta Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Avacta Group-33,961.06% -2,929.47% -21.80%
Oxford Nanopore Technologies -54.66%-35.45%-14.42%

In the previous week, Avacta Group had 1 more articles in the media than Oxford Nanopore Technologies. MarketBeat recorded 2 mentions for Avacta Group and 1 mentions for Oxford Nanopore Technologies. Oxford Nanopore Technologies' average media sentiment score of 1.33 beat Avacta Group's score of 0.00 indicating that Oxford Nanopore Technologies is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Avacta Group
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Oxford Nanopore Technologies
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Avacta Group has higher earnings, but lower revenue than Oxford Nanopore Technologies. Oxford Nanopore Technologies is trading at a lower price-to-earnings ratio than Avacta Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Avacta Group£113K3,026.90-£30.08M-£9.66N/A
Oxford Nanopore Technologies£235M6.49-£175.21M-£12.50N/A

3.1% of Avacta Group shares are owned by institutional investors. Comparatively, 18.9% of Oxford Nanopore Technologies shares are owned by institutional investors. 47.7% of Avacta Group shares are owned by insiders. Comparatively, 2.5% of Oxford Nanopore Technologies shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Avacta Group has a beta of 1.12, meaning that its stock price is 12% more volatile than the broader market. Comparatively, Oxford Nanopore Technologies has a beta of 0.956, meaning that its stock price is 4% less volatile than the broader market.

Avacta Group currently has a consensus target price of GBX 99, indicating a potential upside of 35.62%. Oxford Nanopore Technologies has a consensus target price of GBX 198.60, indicating a potential upside of 27.29%. Given Avacta Group's stronger consensus rating and higher possible upside, analysts plainly believe Avacta Group is more favorable than Oxford Nanopore Technologies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Avacta Group
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Oxford Nanopore Technologies
0 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.83

Summary

Avacta Group beats Oxford Nanopore Technologies on 9 of the 16 factors compared between the two stocks.

How does Oxford Nanopore Technologies compare to Horizon Discovery Group plc (HZD.L)?

Oxford Nanopore Technologies (LON:ONT) and Horizon Discovery Group plc (HZD.L) (LON:HZD) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, institutional ownership, valuation, dividends, earnings, profitability and media sentiment.

In the previous week, Oxford Nanopore Technologies had 1 more articles in the media than Horizon Discovery Group plc (HZD.L). MarketBeat recorded 1 mentions for Oxford Nanopore Technologies and 0 mentions for Horizon Discovery Group plc (HZD.L). Oxford Nanopore Technologies' average media sentiment score of 1.33 beat Horizon Discovery Group plc (HZD.L)'s score of 0.00 indicating that Oxford Nanopore Technologies is being referred to more favorably in the media.

Company Overall Sentiment
Oxford Nanopore Technologies Positive
Horizon Discovery Group plc (HZD.L) Neutral

Horizon Discovery Group plc (HZD.L) has a net margin of 0.00% compared to Oxford Nanopore Technologies' net margin of -54.66%. Horizon Discovery Group plc (HZD.L)'s return on equity of 0.00% beat Oxford Nanopore Technologies' return on equity.

Company Net Margins Return on Equity Return on Assets
Oxford Nanopore Technologies-54.66% -35.45% -14.42%
Horizon Discovery Group plc (HZD.L) N/A N/A N/A

18.9% of Oxford Nanopore Technologies shares are held by institutional investors. 2.5% of Oxford Nanopore Technologies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Horizon Discovery Group plc (HZD.L) has lower revenue, but higher earnings than Oxford Nanopore Technologies. Oxford Nanopore Technologies is trading at a lower price-to-earnings ratio than Horizon Discovery Group plc (HZD.L), indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Oxford Nanopore Technologies£235M6.49-£175.21M-£12.50N/A
Horizon Discovery Group plc (HZD.L)£54.63M0.00N/A-£5.50N/A

Oxford Nanopore Technologies presently has a consensus target price of GBX 198.60, indicating a potential upside of 27.29%. Given Oxford Nanopore Technologies' stronger consensus rating and higher possible upside, equities analysts clearly believe Oxford Nanopore Technologies is more favorable than Horizon Discovery Group plc (HZD.L).

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Oxford Nanopore Technologies
0 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.83
Horizon Discovery Group plc (HZD.L)
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Summary

Oxford Nanopore Technologies beats Horizon Discovery Group plc (HZD.L) on 9 of the 13 factors compared between the two stocks.

Get Oxford Nanopore Technologies News Delivered to You Automatically

Sign up to receive the latest news and ratings for ONT and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ONT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ONT vs. The Competition

Export
MetricOxford Nanopore TechnologiesBiotechnology IndustryHealthcare SectorLON Exchange
Market Cap£1.53B£3.86B£7.16B£2.87B
Dividend YieldN/A3.63%2.56%6.23%
P/E Ratio-12.4814.11272.98366.83
Price / Sales6.491,477.47654.9983,599.70
Price / Cash4.04106.6877.0427.89
Price / Book2.3215.1310.336.33
Net Income-£175.21M-£22.82M£3.49B£5.89B
7 Day Performance-1.72%-4.31%-3.33%-0.69%
1 Month Performance22.66%0.00%-0.42%0.18%
1 Year Performance-6.30%40.67%19.22%20.03%

Oxford Nanopore Technologies Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ONT
Oxford Nanopore Technologies
3.4924 of 5 stars		GBX 156.02
+2.2%		GBX 198.60
+27.3%		-8.7%£1.53B£235MN/A1,281
ABC
Abcam
N/AN/AN/AN/A£2.81B£350.40M20,433.331,650
OXB
Oxford Biomedica
2.5224 of 5 stars		GBX 442.25
-1.1%		GBX 580.85
+31.3%		-26.0%£535.29M£168.74MN/A891
SLN
Silence Therapeutics
N/AN/AN/AN/A£480.35M£11.35MN/A100
AVCT
Avacta Group
1.7347 of 5 stars		GBX 69
+1.5%		GBX 99
+43.5%		+32.7%£323.30M£113KN/A120

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:ONT) was last updated on 9/12/2026 by MarketBeat.com Staff.
From Our Partners
Elon’s “nude” scandal – a big opportunity?
Elon Musk's SpaceX just hit a legal snag in Minnesota over Grok's AI nudification capabilities, with the state...
InvestorPlace | Sponsoredtc pixel
Why I'm NOT Buying the SpaceX IPO (And What I'm Buying Instead)
Don't buy Nvidia... Not when the AI companies that will define the next decade are selling for pennies. You wo...
Decentralized Masters | Sponsoredtc pixel
BlackRock and Vanguard already own THIS
Institutions own roughly 88 percent of an overlooked American oil and natural gas company. BlackRock holds 32 ...
Monument Traders Alliance | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Gold majors have a big problem
Newmont spent 15 billion dollars acquiring Newcrest in 2023, the largest deal in gold mining history. Yet prod...
Golden Portfolio | Sponsoredtc pixel
Shocking AI prediction from the “Billionaire Whisperer"
Marc Chaikin's Power Gauge system flagged Micron before it soared 970 percent, Celestica before a 6,600 percen...
Chaikin Analytics | Sponsoredtc pixel
After KDA, PRE, and OCEAN—this is the one
17,556% on KDA. Here's what I'm buying now. It's a coin under $1.00 that most investors have never heard of...
Crypto 101 Media | Sponsoredtc pixel